| Literature DB >> 34233904 |
Sevil Savaş Erdoğan1, Filiz Cebeci Kahraman2.
Abstract
In Turkey, diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine has been administered to all children in the second, fourth, sixth and 18th months within the scope of the national vaccination programme. Here we present a rare case of fixed drug eruption (FDE) that occurred as a result of the administration of a pentavalent DTaP-IPV-Hib combined vaccine in a 4-month-old girl. There was no history of taking any other medication before or when the lesion appeared. The lesion responded well to 1 week of topical methylprednisolone aceponate cream application and regressed within 1 week, leaving mild hyperpigmentation. Few cases of FDE have been reported occurring after administration of various vaccines and it is extremely rare in children. To our knowledge, this is the first reported case of FDE developing in an infant after the combined pentavalent DTaP-IPV-Hib vaccine. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: allergy and immunology; case reports; clinical medicine; dermatology; drug-related side effects and adverse reactions; pediatrics; primary health care; public health
Year: 2021 PMID: 34233904 DOI: 10.1136/ejhpharm-2021-002875
Source DB: PubMed Journal: Eur J Hosp Pharm ISSN: 2047-9956